Hikma Pharmaceuticals PLC reiterated earnings guidance for the year 2024. For the year, expected Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $660 million to $700 million in 2024, in line with prior guidance.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,973 GBX | +0.87% | +2.55% | +10.29% |
03/05 | Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy | MT |
03/05 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.29% | 5.44B | |
+32.95% | 700B | |
-4.97% | 358B | |
+18.83% | 330B | |
+3.54% | 287B | |
+15.70% | 236B | |
+6.68% | 202B | |
-9.08% | 197B | |
+6.70% | 161B | |
-1.81% | 157B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals plc Reiterates Earnings Guidance for the Year 2024